| Development Cohort (226) | Validation cohort (51) | P value | |
---|---|---|---|---|
Training Set (164) | Test Set (62) | |||
Age | Â | Â | Â | 0.543 |
 Mean ± SD | 61.1 ± 8.7 | 63.9 ± 6.4 | 60.7 ± 9.2 |  |
Gender | Â | Â | Â | 0.017 |
 Male (%) | 80(48.8) | 35(56.5) | 36(70.6) |  |
 Female (%) | 84(51.2) | 27(43.5) | 15(29.4) |  |
Pathological TNM stage | Â | Â | Â | 0.319 |
 IA (%) | 102(62.2) | 38(43.5) | 36(70.6) |  |
 IB (%) | 62(37.8) | 24(56.5) | 15(29.4) |  |
Grade stage | Â | Â | Â | 0.062 |
 1(%) | 87(53.1) | 35(56.5) | 31(60.8) |  |
 2(%) | 15(9.1) | 9(14.5) | 10(19.6) |  |
 3(%) | 62(37.8) | 18(29.0) | 10(19.6) |  |
STAS | Â | Â | Â | 0.099 |
 Yes (%) | 91(55.5) | 27(43.5) | 26(51.0) |  |
 No (%) | 73(44.5) | 35(56.5) | 25(49.0) |  |
RFS status | Â | Â | Â | - |
 Relapse (%) | 25(15.2) | 8(12.9) | 10(19.6) |  |
 No relapse (%) | 139(84.8) | 54(87.1) | 41(80.4) |  |
RFS time (Month) | Â | Â | Â | - |
 Median (IQR) | 40.2(34.5–51.9) | 40.9(35.5–50.5) | 38.7(35.4–40.6) |  |